此次功能提升將增加「RADR ®」250億個腫瘤學數據點和20多種演算法「RADR ®」藥物開發模組能在2年內將ADC候選藥物從發現階段推進到首次人體臨床試驗新型抗體藥物複合體(ADC)將有效抗癌小分子標靶遞送至癌細胞 原文 Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates 出處 Businesswire 連結 https://twitter.com/aimedadviser/status/1626027124762234880 序號 2969
